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Background: Dendritic cells (DCs) play a major role as regulators of inflammatory events associated with thyroid
pathology. The immunoregulatory function of DCs depends strongly on their subtype, as well as maturation and
activation status. Numerous hormonal factors modulate the immune properties of DCs, however, little is known
about effects exerted by the hypothalamus-pituitary-thyroid-axis. Recently, we have shown a direct regulatory
influence of thyroid hormones (TH) on human DCs function. The aim of the present study was to analyze the effect
of systemically administered thyrotropin (TSH) on human blood DCs ex vivo.
Methods: Blood samples for the cytometric analysis of peripheral blood plasmacytoid and myeloid DCs subtypes
were collected from patients subjected to total thyroidectomy because of differentiated thyroid carcinoma at 2
time points: (i) directly before the commencement of TSH administration and (ii) 5 days after first TSH injection. The
whole blood quantitative and phenotypic analysis of plasmacytoid and myeloid DCs subtypes was performed by
flow cytometry.
Results: Administration of TSH did not influence the percentage of plasmacytoid DCs in peripheral blood of study
participants. Also the percentage of the two main myeloid DCs subpopulations – CD1c/BDCA1+ DCs and CD141/
BDCA3+ DCs did not change significantly. TSH administration had no effect on the surface expression of CD86 –
one of the major costimulatory molecules – neither in the whole peripheral blood mononuclear cell (PBMC)
fraction nor in particular DCs subtypes.
Conclusions: In the present study, we demonstrated no influence of systemic TSH administration on human
peripheral blood DCs subtypes. These results are in accordance with our previous work suggesting the direct effect
of TH on human DCs ex vivo.
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A complex network of immune-endocrine interactions
involving numerous cell types, humoral immune media-
tors and different hormonal systems participate in many
of the physiological processes and, when disbalanced, also
in pathological mechanisms leading to various disorders,
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reproduction in any medium, provided the orinfertility [1–3]. The influence of immune system on
thyroid function has extensively been investigated in se-
veral experimental models of autoimmune thyroid disease,
as well as in multiple cases of human thyroid tumors.
Increasing body of evidence underlines the pivotal role of
dendritic cells (DCs) as regulators of inflammatory events
associated with thyroid pathology [4–6]. Interestingly, in
animal models of spontaneous thyroiditis an accumulation
of DCs in thyroid has been shown prior to autoantibody
occurrence and clinical signs [7], suggesting their engage-
ment in the earliest phases of pathological events. The
extraordinary regulatory properties of DCs depend stronglyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ably between particular DCs subtypes of which the most
important in human settings are myeloid and plasmacytoid
DCs (mDCs and pDCs, respectively) [8]. Recently we have
shown for the first time a regulatory action of thyroid hor-
mones (TH) on naturally occurring human peripheral
blood DCs [9]. For that purpose we compared ex vivo the
phenotype and immunoregulatory properties of peripheral
blood DCs subtypes in thyroidectomized patients in two
thyrometabolic states – during withdrawal of L-thyroxine
(L-T4) treatment and, subsequently, after administration of
L-T4 for 2–3 months. In this experimental model, we
observed that the supplementation of L-T4 resulted in a
significant quantitative increase of plasmacytoid and mye-
loid DCs circulating in patients’ peripheral blood, as well
as in an up-regulation of the surface expression of CD86
co-stimulatory molecule (regarded as the main DCs matur-
ation marker) on both DCs subtypes. Similar effects of TH
supplementation were also observed in culture experi-
ments with magnetically sorted human peripheral blood
DCs. Although the results of in vitro experiments con-
firmed the direct influence of TH on DCs, the role of
TSH fluctuations in vivo in the immunological observa-
tions associated with TH treatment could not be fully
excluded [9].
The aim of this study was to further investigate the
influence of TSH on the structure and co-stimulatory
phenotype of human peripheral blood DCs subtypes
ex vivo. The study was performed in patients thyroidec-
tomized because of differentiated thyroid carcinoma and
qualified for recombinant human TSH (rhTSH) adminis-
tration from standard indications. This unique clinical
model, encompassing cytometric analysis of peripheral
blood obtained before and after rhTSH administration,
allowed the ex vivo assessment of TSH influence on
human DCs subtypes under stable TH concentrations.
Methods
Patients
The study participants were recruited from the Depart-
ment of Endocrinology and Metabolic Diseases, Polish
Mother’s Memorial Hospital – Research Institute in
Lodz. Prior to the enrolment, all of the participants
signed an informed consent, according to the study
protocol approved by the local Ethics Committee. The
study group included 24 patients (19 women and 5 men,
age 50,6 ± 12,75 years, mean ± SD) thyroidectomized be-
cause of differentiated thyroid carcinoma (papillary thy-
roid carcinoma, n = 22 or follicular thyroid carcinoma,
n = 2). Total thyroidectomies were performed earlier
[mean time period before our study 7,17 ± 5,2 years
(mean ± SD; range: 1–20 years)]. The patients with
metastases, immunological or metabolic disorders
(i.e. diabetes mellitus), as well as patients with clinical orlaboratory signs of ongoing inflammatory processes were
excluded from the study. At the time of study participa-
tion, the patients received rhTSH (Thyrogen, Genzyme
Corporation; 0.9 mg i.m., followed by second 0.9 mg i.m.
injection 24 hours later) as a routine control of potential
thyroid cancer activity.
Peripheral blood samples were collected between
08.00 and 09.00 AM after an overnight fast. Venous
blood was obtained by clean venipuncture (needle gauge
19), avoiding slow flowing draws and/or traumatic veni-
punctures. The blood samples were collected from the
same patient (n = 24) at two (2) consecutive time points:
(i) directly before the commencement of rhTSH admi-
nistration and (ii) five (5) days after first rhTSH
injection.
Free triiodothyronine (FT3), free thyroxine (FT4) and
TSH concentrations were measured by the immunoradio-
metric (IRMA) method with appropriate kits (BRAHMS,
Berlin, Germany; range normal values: TSH: 0.27–4.2
mIU/L; FT3: 2,6–4,4 pg/mL; FT4: 0,93–1,7 ng/dL). The
concentration of thyroglobulin (Tg) was assessed with
Elecsys Tg reagent kit and Cobas e 411 analyser (Roche
Diagnostic Mannheim, Germany) and the concentration
of Tg antibody was measured by the electrochemilumines-
cence (ECLIA) method with appropriate kits (Roche Diag-
nostic Mannheim, Germany, normal value: Tg antibody
< 115 IU/ml) and equipment (Modular Analytics E170 -
Roche Diagnostic).
Fluorescence-activated cell sorting (FACS) analysis
Whole blood samples obtained from study participants
were assessed on the same day by flow cytometry, using
a FACSCanto IIW cytometer and FACSDivaW software
(BD Biosciences, San Jose, CA, USA). Peripheral blood
DCs subsets can be recognized on the basis of surface
expression pattern of blood dendritic cell antigens
(BDCAs). Two distinct populations of mDCs are charac-
terized by expression of: BDCA1 (which has been shown
to be identical to CD1c) – mDC1, or CD141/BDCA3 –
mDC2. In contrast, BDCA2 and BDCA4 are specific for
blood pDCs [10–12]. Monoclonal antibodies (mAb) spe-
cific for BDCA antigens were purchased from Miltenyi
Biotec (Bergisch Gladbach, Germany). All remaining
mAb and appropriate isotype controls were purchased
from BD Biosciences Pharmingen (San Jose, CA, USA).
The staining of peripheral blood DCs subtypes was per-
formed as described earlier [13,14]. Shortly, the BDCA2+
plasmacytoid DCs and the BDCA3+ myeloid DCs subtypes
were recognized by staining with allophycocyanin (APC)
conjugated antibodies specific for BDCA2 (AC144, mouse
IgG1), and BDCA3 (AD5-14H12, mouse IgG1), respect-
ively. The CD1c/BDCA1+ subtype was recognized as a
population positive for anti-BDCA1-APC (AD5-8E7,
mouse IgG2a) and negative for anti-CD19-PerCP-Cy5.5
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were counterstained with phycoerythrin (PE) conjugated
mAb: anti-CD11c (B-ly6, mouse IgG1) and anti-CD86
(2331/FUN-1, mouse IgG1). After the incubation with
mAb erythrocytes were lysed (15 minutes at room
temperature) with FACS Lysing Solution (BD Biosciences,
San Jose, CA, USA). The leukocyte fraction was then
washed twice with cold phosphate buffered saline
(PBS), counted and suspended in PBS for FACS ana-
lysis. To avoid an unspecific antibody-binding, a FcR-
blocking reagent (Miltenyi Biotec, Bergisch Gladbach,
Germany) was applied in all analyses. DCs subpopula-
tions were analyzed in a blinded way and the results
were expressed as a percentage of peripheral blood
mononuclear cells (PBMC) fraction.
Statistical analysis
Statistical analysis was performed using the Prism 5.0
statistical software (GraphPad, La Jolla, CA, USA). The
normality of distribution was assessed utilizing the
Shaphiro-Wilk test and the differences in peripheral
blood cell populations were analyzed with the Wilcoxon
matched-pairs signed rank test. In all the analyses,




All the study participants received suppressive L-T4
treatment (mean L-T4 dose: 150 ± 32.8 μg/day ±SD). At
the commencement of the study the serum concentra-
tion of FT3 was 3,39 ± 0,6 pg/mL (mean ± SD), concen-
tration of FT4 was 1,92 ± 0,4 ng/dL and the serum
concentration of TSH was 0,18 ± 0,3 mIU/L (range of nor-
mal values: FT3: 2,6–4,4 pg/mL; FT4: 0,93–1,7 ng/dL;
TSH: 0.27–4.2 mIU/L). The serum Tg concentration
assessed five (5) days after the first rhTSH injection, as an
indirect measure of malignant process activity, did not
show pathological results in any of the study participants.
















Figure 1 The influence of TSH on distribution of human peripheral bl
mDCs (B) in the whole PBMC fraction of patients (n = 24) directly before co
rhTSH injection (post).concentration of Tg antibody was 28,59 ± 68,4 IU/ml
(normal value: Tg antibody < 115 IU/ml).
The percentage of human peripheral blood DCs subtypes
was not influenced by rhTSH administration
The administration of rhTSH did not influence the
percentage of plasmacytoid DCs in peripheral blood of
study participants (0.513 ± 0.238% vs. 0.609 ± 0.495%;
p = 0.41). Also the percentage of the main myeloid
DCs population – CD1c/BDCA1+ mDCs did not change
significantly after rhTSH injections (0.657 ± 0.219% vs.
0.787 ± 0.681%; p = 0.88) as compared to the value dir-
ectly before therapy commencement (Figure 1). In ac-
cordance with earlier observations, the percentage of the
second myeloid DCs population – CD141/BDCA3+
mDCs was very low in all the patients and did not show
any significant quantitative fluctuations during the study
(0.1 ± 0.02% vs. 0.1 ± 0.03%; p = 1.0).
Administration of rhTSH did not change maturation state
of human peripheral blood DCs subtypes
In order to better characterize the potential effect of
TSH on human DCs subtypes, we performed an assess-
ment of surface expression of CD86 – one of the major
co-stimulatory molecules, regarded as DCs maturation
marker. In our analysis the administration of rhTSH did
not influence the level of CD86 expression in the whole
PBMC population (Figure 2A). Also the percentage of
CD86 positive pDCs and CD1c/BDCA1+ mDCs did
not change after rhTSH injection (28.98 ± 15.44% vs.
30.54 ± 16.28%; p = 0.53 and 81.57 ± 9.96% vs. 77.47 ±
9.54%; p = 0.08, respectively) (Figure 2B and C). Due to
the very low numbers of CD141/BDCA3+ mDCs the
expression of CD86 could not be analyzed statistically
in this population.
Discussion
Numerous hormonal factors including androgens, estro-
gens, progesterone, glucocorticosteroids and vitamin D
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Figure 2 The influence of TSH on CD86 expression in
peripheral blood. The precentage of CD86 positive cells (A), pDCs
(B) and CD1c/BDCA+ mDCs (C) in the whole PBMC fraction of
patients (n = 24) directly before commencement of rhTSH
administration (pre) and 5 days after first rhTSH injection (post).
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[15–18]. However, very little is known about the influ-
ence of hypothalamus-pituitary-thyroid axis on DCs
subtypes and their biological function. Lately, expression
of TH receptor was reported in murine bone marrow
derived DCs. The in vitro experiments showed that T3
stimulation resulted in TH-receptor depended activationof NF-κB and Akt transcriptional pathways and influ-
enced maturation and immune function of these cells
[19,20]. Interestingly, the direct immunostimulatory
effect of T3 on murine DCs could be prevented by
glucocorticosteroids in mechanism involving down-
regulation of TH-receptor expression, as well as inhi-
bition of Akt and NF-κB signaling [21]. In our recent
work, we have demonstrated similar stimulatory influ-
ence of TH on human peripheral blood DCs both
ex vivo and in vitro. Although the in vitro experiments
confirmed the direct nature of TH action on human
DCs, we could not fully exclude that the immunomodu-
latory effects observed ex vivo, were partially dependent
on serum TSH fluctuations associated with L-T4 treat-
ment [9]. TSH receptor expression was described earlier
on murine DCs and TSH stimulation was shown to
augment the phagocytic properties and secretion of
proinflammatory cytokines (IL1-beta and IL-12) by DCs
[22]. In human settings, expression of TSH receptor was
presented most recently in pluripotent bone marrow
mesenchymal stem cells [23] but there is little know-
ledge about TSH receptor expression in hematopoietic
lineages and main human leukocyte subsets. In our
present work we have performed for the first time an
analysis of the influence of TSH on human peripheral
blood DCs subsets ex vivo. The unique clinical model,
based on the thyroidectomized patients receiving sys-
temically rhTSH, provided the most natural, independ-
ent from TH fluctuations, experimental conditions for
such assessment in humans. In contrast to the results of
the aforementioned animal study in vitro, in our experi-
ments we did not observe any significant influence of
TSH on human peripheral blood DCs ex vivo. Systemic
administration of rhTSH did not cause any significant
quantitative changes in the assessed plasmacytoid and
myeloid DCs subpopulations. Also the level of CD86
surface expression on particular DCs subsets was not
influenced by rhTSH. Beside the obvious species diffe-
rences, the lack of effect of systemic rhTSH administra-
tion on peripheral blood DCs observed in our study may
suggest that the TSH-DCs interaction reaches its signifi-
cance rather on the level of local, organ-specific, regula-
tory circuits. This suggestion stays in accordance with
results of experimental studies performed on DCs
isolated from the thyroid gland. It was shown that the
maturation state and proliferative response of thyroid
derived DCs co-cultured in vitro with thyrocytes
depended strongly on TSH stimulation and humoral
factors secreted by thyrocytes (GM-SCF and TGF-beta)
[24,25]. The dominant role of auto- and paracrine TSH
stimulation in DCs biology seems to be also supported
by observations that DCs represent an effective local
source of TSH under physiological and inflammatory
conditions [26,27].
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Results of this study are in concordance with the direct,
independent from TSH, effect of TH on human peri-
pheral blood DC subtypes suggested by the results of
our previous experiments ex vivo. This observation
extends the knowledge about the regulatory processes of
human DCs function and may be of great importance in
research directed on DCs based therapeutic approaches.
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